黄焰, 曾敏. 乳腺癌新辅助化疗再认识[J]. 中国肿瘤临床, 2016, 43(15): 643-645. DOI: 10.3969/j.issn.1000-8179.2016.15.419
引用本文: 黄焰, 曾敏. 乳腺癌新辅助化疗再认识[J]. 中国肿瘤临床, 2016, 43(15): 643-645. DOI: 10.3969/j.issn.1000-8179.2016.15.419
Yan HUANG, Min ZENG. Reconsidering the use of neoadjuvant chemotherapy in breast cancer[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2016, 43(15): 643-645. DOI: 10.3969/j.issn.1000-8179.2016.15.419
Citation: Yan HUANG, Min ZENG. Reconsidering the use of neoadjuvant chemotherapy in breast cancer[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2016, 43(15): 643-645. DOI: 10.3969/j.issn.1000-8179.2016.15.419

乳腺癌新辅助化疗再认识

Reconsidering the use of neoadjuvant chemotherapy in breast cancer

  • 摘要: 近年来随着乳腺癌新辅助化疗研究的深入,该治疗手段已在临床被广泛应用。新辅助化疗使不可手术的局部晚期乳腺癌患者获得手术治疗的机会,并且提高具有较大肿瘤体积患者的保乳率,从而明显改善患者的生存质量,但仍有许多问题存在争议。本文将对乳腺癌新辅助化疗相关临床研究、以及对新辅助化疗的再认识进行综述。

     

    Abstract: With the intense development of neoadjuvant chemotherapy for breast cancer research in recent years, this approach has been used widely in clinical treatment. Neoadjuvant chemotherapy can increase the chance of operation for patients with locally advanced breast cancer. Moreover, it can improve breast-conserving rate in larger-tumor patients, thereby improving the quality of life of these patients. However, some controversies regarding the use of neoadjuvant chemotherapy for breast cancer patients remain to be resolved. This review focuses on clinical studies and re-recognition of neoadjuvant chemotherapy as a viable treatment for breast cancer.

     

/

返回文章
返回